Alzheimer’s Disease and Toxins Produced by Marine Dinoflagellates: An Issue to Explore

Alzheimer’s Disease and Toxins Produced by Marine Dinoflagellates: An Issue to Explore

This paper examined the toxins naturally produced by marine dinoflagellates and their effects on increases in β-amyloid plaques along with tau protein hyperphosphorylation, both major drivers of Alzheimer’s disease (AD). This approach is in line with the demand for certain natural compounds, namely...

Full description

Bibliographic Details
Main Authors:	Maria João Botelho, Jelena Milinovic, Narcisa M. Bandarra, Carlos Vale
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Marine Drugs
Subjects:	Alzheimer’s disease marine dinoflagellates phycotoxins β-amyloid plaques hyperphosphorylated tau protein
Online Access:	https://www.mdpi.com/1660-3397/20/4/253

Similar Items

Cutibacterium Acnes induces Alzheimer’s disease-like pathology in brains of wistar rats through structural changes associated with microtubules
by: Morteza Aliashrafi, et al.
Published: (2024-11-01)

1,8-Cineole Ameliorates Advanced Glycation End Products-Induced Alzheimer’s Disease-like Pathology In Vitro and In Vivo
by: Fengmao An, et al.
Published: (2022-06-01)

Impaired glymphatic clearance is an important cause of Alzheimer’s disease
by: Iyawnna Hazzard, et al.
Published: (2024-10-01)

Traditional Chinese medicine in Alzheimer's disease: From the perspective of GSK-3β and Tau hyperphosphorylation
by: Mei Wang, et al.
Published: (2024-12-01)

Natural bioactive compounds form herbal medicine in Alzheimer’s disease: from the perspective of GSK-3β
by: Mei Wang, et al.
Published: (2025-02-01)

The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer’s Disease
by: Yan H, et al.
Published: (2023-11-01)

Developments in the Role of Iron Imbalance in the Pathogenesis of Alzheimer's Disease
by: GUO Shuang, CHEN Fengyan, YIN Xiang, WANG Lu, GUO Xuefeng, YU Qiming, ZOU Zhenyou, SHU Wei
Published: (2022-01-01)

Industrial Applications of Dinoflagellate Phycotoxins Based on Their Modes of Action: A Review
by: Kichul Cho, et al.
Published: (2020-12-01)

LC-MS/MS Method Development for the Discovery and Identification of Amphidinols Produced by <i>Amphidinium</i>
by: Marvin Wellkamp, et al.
Published: (2020-09-01)

Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
by: Kaden L. Nystuen, et al.
Published: (2024-01-01)

Untangling Tau: Molecular Insights into Neuroinflammation, Pathophysiology, and Emerging Immunotherapies
by: Ryder Davidson, et al.
Published: (2023-11-01)

Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer’s Disease
by: Victoria García-Morales, et al.
Published: (2021-12-01)

A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau
by: Zhouquan Jiang, et al.
Published: (2024-01-01)

Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
by: Eliasz Engelhardt, et al.
Published: (2024-12-01)

Ventriculoperitoneal shunt patients and glaucoma: a cohort analysis of the NPH registry
by: Benjam Kemiläinen, et al.
Published: (2024-07-01)

Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
by: Yuanxin Zhao, et al.
Published: (2022-07-01)

A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau
by: Yang Gao, et al.
Published: (2023-11-01)

Effect of N-Acetyl Cysteine as an Adjuvant Treatment in Alzheimer’s Disease
by: Sarah Monserrat Lomelí Martínez, et al.
Published: (2025-02-01)

Nec‐1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice
by: Seung‐Hoon Yang, et al.
Published: (2016-11-01)

A biomimetic upconversion nanoreactors for near-infrared driven H2 release to inhibit tauopathy in Alzheimer's disease therapy
by: Qin Zhang, et al.
Published: (2024-12-01)

The Potential Mechanism and the Role of Antioxidants in Mitigating Oxidative Stress in Alzheimer’s Disease
by: Rayees Ahmad Naik, et al.
Published: (2025-02-01)

he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments
by: I. V. Litvinenko, et al.
Published: (2019-11-01)

Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition
by: Layal Abou Assi, et al.
Published: (2024-07-01)

Rhei Undulati Rhizoma attenuates memory decline and reduces amyloid-β induced neuritic dystrophy in 5xFAD mouse
by: Seungmin Lee, et al.
Published: (2024-07-01)

The Possible Roles of the Dentate Granule Cell’s Leptin and Other Ciliary Receptors in Alzheimer’s Neuropathology
by: James F. Whitfield, et al.
Published: (2015-07-01)

Hyperphosphorylated tau targeting human serum albumin Fusion protein as therapeutics for Alzheimer’s diseases
by: Sookhee Bang, et al.
Published: (2024-12-01)

An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease
by: Yashumati Ratan, et al.
Published: (2023-05-01)

Unraveling the therapeutic efficacy of resveratrol in Alzheimer’s disease: an umbrella review of systematic evidence
by: Ali Azargoonjahromi, et al.
Published: (2024-03-01)

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer’s disease model mice
by: Dongping Yao, et al.
Published: (2024-06-01)

Gambierone and Sodium Channel Specific Bioactivity Are Associated with the Extracellular Metabolite Pool of the Marine Dinoflagellate <i>Coolia palmyrensis</i>
by: Alexander K. Leynse, et al.
Published: (2023-04-01)

Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer’s Disease Model
by: Kunie Ando, et al.
Published: (2025-01-01)

Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease
by: Ahmed M. Elshazly, et al.
Published: (2023-07-01)

Decreased serum PF4 levels correlate with cognitive decline and CSF biomarkers in Alzheimer's disease in a Chinese cohort
by: Hao Sun, et al.
Published: (2025-03-01)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
by: Nicholas J. Ashton, et al.
Published: (2019-12-01)

Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
by: Débora A. Moreira, et al.
Published: (2023-03-01)

Updates in Alzheimer's disease: from basic research to diagnosis and therapies
by: Enjie Liu, et al.
Published: (2024-09-01)

First Identification of Amphidinols from Mexican Strains and New Analogs
by: Lorena M. Durán-Riveroll, et al.
Published: (2023-02-01)

Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer’s disease: a longitudinal study
by: Fardin Nabizadeh, et al.
Published: (2024-07-01)

Mammalian Models in Alzheimer’s Research: An Update
by: Himadri Sharma, et al.
Published: (2023-10-01)

Self-assembled low molecular weight chitosan-bilobalide microsuspension protects hippocampal toxicity in amyloid beta(25–35) induced mice
by: P. Pramod Kumar, et al.
Published: (2024-12-01)